Globe Newswire (Wed, 8-Apr 7:47 AM ET)
Globe Newswire (Mon, 6-Apr 9:17 AM ET)
Globe Newswire (Thu, 2-Apr 8:07 AM ET)
Globe Newswire (Mon, 30-Mar 5:35 PM ET)
Globe Newswire (Wed, 18-Mar 8:00 AM ET)
Curanex Expands Scientific Advisory Board With Two Distinguished Researchers
Globe Newswire (Thu, 12-Mar 9:30 AM ET)
Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board
Globe Newswire (Wed, 11-Mar 8:00 AM ET)
Curanex Forms World Class Scientific Advisory Board
Globe Newswire (Thu, 5-Mar 8:00 AM ET)
Market Chameleon (Thu, 26-Feb 4:53 AM ET)
Curanex Provides Operational Update on Key Regulatory Milestones
Globe Newswire (Wed, 25-Feb 8:00 AM ET)
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.
Curanex Pharmaceuticals trades on the NASDAQ stock market under the symbol CURX.
As of April 10, 2026, CURX stock price declined to $0.46 with 34,384 million shares trading.
CURX has a beta of -0.64, meaning it tends to be less sensitive to market movements. CURX has a correlation of 0.00 to the broad based SPY ETF.
CURX has a market cap of $13.14 million. This is considered a Sub-Micro Cap stock.
CURX support price is $.43 and resistance is $.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CURX shares will trade within this expected range on the day.
